Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2016-01-05 Major Shareholding Noti…
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Change in substantial holding 4 pages 127.5KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 filed under the Corporations Act 2001 Section 671B, titled 'Notice of change of interests of substantial holder.' It details changes in voting power and relevant interests of a substantial shareholder (Allan Gray Australia Pty Ltd) in Phosphagenics Limited. The form includes tables listing related bodies corporate, funds managed, changes in relevant interests, and current relevant interests. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category 'Major Shareholding Notification' (MRQ). The document is not an annual report, earnings release, or any other financial report but a regulatory notice about shareholding changes.
2016-01-05 English
Phosphagenics Initiates Arbitration Against Mylan 2 pages 51.5KB
Legal Proceedings Report Classification · 100% confidence The document is an announcement from Phosphagenics Limited regarding the initiation of arbitration against Mylan Laboratories Limited. It details the legal dispute, the basis of the claims, and the expected timeline for arbitration. There is no financial data, no report attached or referenced as being published, and no mention of financial results or management changes. The content focuses on legal proceedings and dispute resolution. Therefore, this document fits the category of Legal Proceedings Report (LTR).
2016-01-05 English
Response to ASX Price Query 5 pages 1.1MB
Regulatory Filings
2016-01-04 English
Phosphagenics' PHN Trial Completes Enrolment and Dosing 2 pages 342.0KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Phosphagenics Limited reporting the completion of patient recruitment and dosing in a Phase 2a clinical trial for their TPM/Oxycodone topical patch. It provides details about the study, expected timing of headline results, and forward-looking statements about the product's potential. There are no financial statements, detailed financial analysis, or regulatory filings such as annual or quarterly reports. The content is an update on a clinical trial progress and related business outlook, typical of a Capital/Financing Update or general company progress announcement. Given the focus on trial progress and future expectations rather than financial results or governance, the best fitting category is Capital/Financing Update (CAP). The document length is moderate and contains substantive information about the trial completion, not just a brief notice or report publication announcement. Confidence is high due to clear content focus on clinical trial progress and business implications.
2015-12-16 English
Change of Company Secretary 1 page 41.5KB
Board/Management Information Classification · 100% confidence The document is a short announcement from Phosphagenics Limited dated 4 December 2015, regarding the appointment of a new Company Secretary and the transition of the previous Company Secretary. It contains no financial data, no report or presentation, and no regulatory filings beyond this management change. The content clearly relates to a change in senior management position, specifically the Company Secretary role. Therefore, it fits the category of Board/Management Information (MANG). The document length is only 2010 characters, which is consistent with a brief announcement rather than a full report.
2015-12-03 English
Phosphagenics Initiates Grower/Finisher Pig Study 2 pages 51.0KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Phosphagenics Limited regarding the initiation of a new animal health study (grower/finisher pig study) and expected results timeline. It is a corporate update about ongoing research activities and future expectations, not a financial report, earnings release, or regulatory filing. The document is relatively short (4733 characters) and does not contain financial statements, detailed financial data, or regulatory certifications. It is an announcement of a business development or operational update rather than a formal report or filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other specific categories.
2015-12-02 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.